奥沙利铂或伊立替康联合希罗达治疗晚期胃癌的临床比较分析

Comparison Between the Effects of Oxaliplatin or Irinotecan Combined with Capecitabine in the Treatment of Advanced Gastric Cancer

目的观察并比较奥沙利铂联合希罗达与伊立替康联合希罗达治疗晚期胃癌的近期疗效和毒副反应。方法59例晚期胃癌随机分为两组,A组31例应用奥沙利铂联合希罗达,B组28例应用伊立替康联合希罗达。均化疗2个周期以上。结果A组中CR 1例,PR 14例,有效率为48.39%,中位无进展生存期为6.3个月;B组中CR 0例,PR 13例,有效率为46.43%,中位无进展生存期为5.9个月。两组有效率及中位无进展生存期比较差异均无统计学意义(P>0.05)。两组主要毒副反应为骨髓抑制和胃肠道反应,A组神经毒性较重,B组腹泻较重;两组均无化疗相关性死亡。结论两种方案对晚期胃癌均有较好的疗效,且疗效相当;毒副反应均可耐受。

Objective To observe and compare the recent objective response rate and toxicity of oxaliplatin or irinotecan combined with capecitabine in the treatment of advanced gastric cancer.Methods 59 patients with advanced gastric cancer were randomly divided into two groups.The group A consisted of 31 patients who received oxaliplatin plus capecitabine and the group B consisted of 28 patients received irinotecan plus capecitabine in a 21-day regimen.Two or more cycle chemotherapy was completed in each group.Results In the group A,one patients achieved complete response and 14 patients achieved partial responses.The overall response rate was 48.39%.The median progression free survival time was 6.3 months;in the group B,no patient achieved complete response and 13 patients achieved partial responses.The overall response rate was 46.43%.The median progression free survival time was 5.9 months.There was no significant difference between them.The most common toxicities were myelosuppression and gastrointestinal reaction in the two groups.Patients in the group A experienced more neurotoxicity.On the contrary,the rate of diarrhoea in the group B was more increased.No chemotherapy-related death was observed.Conclusion The effects of oxaliplatin or irinotecan combined with capecitabine in the treatment of advanced gastric cancer are good and comparable,and their toxicities are tolerable.